A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)-Reference-Cited by-同舟云学术

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Published:2014-05-29 Issue:22 Volume:123 Page:3398-3405
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kahl Brad S.¹,Spurgeon Stephen E.²,Furman Richard R.³,Flinn Ian W.⁴,Coutre Steven E.⁵,Brown Jennifer R.⁶,Benson Don M.⁷,Byrd John C.⁷,Peterman Sissy⁸,Cho Yoonjin⁸,Yu Albert⁸,Godfrey Wayne R.⁸,Wagner-Johnston Nina D.⁹

Affiliation:

1. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI;

2. Department of Medicine, Oregon Health and Sciences University, Portland, OR;

3. Department of Medicine, Weill Cornell Medical College, New York, NY;

4. Sarah Cannon Research Institute, Nashville, TN;

5. Stanford University Medical Center, Stanford, CA;

6. Dana-Farber Cancer Institute, Boston, MA;

7. Department of Medicine, Ohio State University, Columbus, OH;

8. Gilead Sciences, Seattle, WA; and

9. Department of Medicine, Washington University School of Medicine, St. Louis, MO

Abstract

Key Points This clinical study assessed idelalisib, a selective PI3Kδ inhibitor, in 40 patients with relapsed/refractory MCL. In a dose-escalation trial in heavily pretreated patients, an overall response rate of 40% was observed with an acceptable safety profile.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/22/3398/1377273/3398.pdf

Reference39 articles.

1. How I treat mantle cell lymphoma.;Ghielmini;Blood,2009

2. Non-Hodgkin lymphoma.;Shankland;Lancet,2012

3. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.;Fisher;Blood,1995

4. Improvement of overall survival in advanced stage mantle cell lymphoma.;Herrmann;J Clin Oncol,2009

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.;Hiddemann;Blood,2005

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. A Novel Role for the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation;The American Journal of Pathology;2024-08

3. Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies;Frontiers in Pharmacology;2024-06-14

4. Targeted Therapies in the Treatment of Mantle Cell Lymphoma;Cancers;2024-05-20

5. Dose optimization for cancer treatments with considerations for late-onset toxicities;Clinical Trials;2024-04-09